

PERSONAL DATA

Name Laura Bonanno
 Work address Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova (IT)
 Phone +390498215553/5931
 E-mail laura.bonanno@iov.veneto.it
 Birth date 20 December 1981

CURRENT WORKING POSITION

Medical Oncologist at Istituto Oncologico Veneto IRCCS

WORK EXPERIENCES

- Dates (from-to) January 2014-today
- Name and address of the employer Medical Oncology 2- Istituto Oncologico Veneto IRCCS
- Occupation or position hold Medical Oncologist (permanent position)
- Dates (from-to) October 2011-December 2013
- Name and address of the employer Medical Oncology 2- Istituto Oncologico Veneto IRCCS
- Occupation or position hold Contract-Medical Oncologist
- Dates (from-to) February-July 2011
- Name and address of the employer Pangaea Biotech S.L. USP, Dexeus University Institute, Barcellona (ES)
- Occupation or position hold Translational research project responsible, under the supervision of Dr. R. Rosell
- Dates (From-To) July 2007-July 2011
- Name and address of the employer Università degli Studi di Padova
- Occupation or position hold Resident in Medical Oncology
- Date (From-to) March 2008
- Name and address of the employer Institute of Cancer Genetics, Columbia University (US)
- Occupation or position hold Training stage, under the supervision of Prof R. Dalla Favera

EDUCATION AND TRAINING

- Dates (from-to) July 2007-July 2011
- Name and type of Organization Università degli Studi di Padova
- Title of qualification awarded Residency in Medical Oncology
- Level 70/70 *cum laude*
- Dates (from-to) November 2006-February 2007
- Name and type of Organization Università degli Studi di Padova
- Title of qualification awarded European Medical Licence (licence number: VE06457)
- Level 270/270
- Dates (From-to) October 2000-July 2006
- Name and type of Organization Università degli Studi di Padova
- Title of qualification awarded Laurea Specialistica in Medicina e chirurgia,
- Level 110/110 *cum laude*

SCIENTIFIC SOCIETIES

- European Society of Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- Associazione Italiana di Oncologia Medica (AIOM)
- European Thoracic Oncology Platform (ETOP)
- International Association for the Study of Lung Cancer (IASLC)

AWARDS AND GRANTS

- 2007: Three-year AIRC scholarship.
 Name of the project: "Angiogenesis as interface between tumor and micro-environment: biological studies in a colorectal cancer model"
- 2010: Ricerca finalizzata ministeriale. Role: collaborator.
 Name of the project: "LKB1/AMPK status and glycolytic phenotype as biomarkers of response of lung cancer to bevacizumab"

- 2016: ELCC travel grant for the abstract: "Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): an exploratory analysis in advanced non-small cell lung cancer (A-NSCLC)"
- 2016 Ricerca finalizzata ministeriale-young researcher. Role: co-principal investigator.
Name of the project: "Tracking the dynamic evolution of ESR1 and PIK3CA mutations on circulating tumor DNA in metastatic breast cancer patients receiving endocrine maintenance treatment: a translational analysis of the prospective multicentre randomized MAIN-A trial".

LANGUAGES

- Mother tongue ITALIAN
- Other languages ENGLISH: excellent reading, writing, speaking
FRENCH: good reading and writing, basic speaking
SPANISH: good reading and speaking, basic writing
GERMAN: basic reading, writing and speaking

CLINICAL TRIALS EXPERIENCE

Involved in both good clinical practice (GCP) and spontaneous phase II and phase III clinical trials, in the field of thoracic oncology

Since 2008 as sub-investigator

Since 2015 as principal-investigator and as sub-investigator.

PUBLICATIONS

- **Bonanno L**, Pavan A, Dieci MV, Di Liso E, Schiavon M, Comacchio G, Attili I, Pasello G, Calabrese F, Rea F, Favaretto A, Rugge M, Guarneri V, Fassan M, Conte PF. *The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3-positive tumor infiltrating lymphocytes*. European Journal of Cancer 2018 (in press) **IF: 7.191**
- Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, **Bonanno L**, Filippazzi V, Leo S, Cinieri S, Ciardiello F, Burgio M A, Bilancia D, Cortinovis D, Rosetti F, Bianco R, Gebbia V, Artioli F, Bordonaro R, Fregoni V, Mencoboni M, Nelli F, Riccardi F, Di Isernia G, Costanzo R, Rocco G, Daniele G, Signoriello S, Piccirillo M C, Gallo C, Perrone F. *Cisplatin-Based First-Line Treatment for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase 3 Trials*. Journal of Clinical Oncology 2018 (in press) **IF: 26.303**
- Frega S, **Bonanno L**, Guarneri V, Conte PF, Pasello G. *Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): towards a less dismal future?* CRO 2018 **IF: 4.495**
- Attili I, Karakaliou N, **Bonanno L**, Berenguer J, Bracth J, Masaoki I, Rosell R. *STAT3 as a potential immunotherapy biomarker in oncogene addicted NSCLC*. Therapeutic advances in medical oncology 2018. **IF: 6.238**
- Metro G, Passaro A, Lo Russo G, **Bonanno L**, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere L F, Giannarelli G, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Parra H S, Morabito A, Chiari R. *Experience with ceritinib in the Italian compassionate use program of patients with crizotinib-refractory, ALK-positive, advanced non-small cell lung cancer*. Future Oncology 2018. **IF: 2.639**
- Attili I, Passaro A, Pavan A, Conte PF, De Marinis F, **Bonanno L**. *Combination immunotherapy strategies in advanced Non-Small Cell Lung Cancer (NSCLC): does biological rationale meet clinical needs?* CROH 2017 **IF: 4.495**
- **Bonanno L**, De Paoli A, Zulato E, Esposito G, Calabrese F, Favaretto A, Santo A, Del Conte A, Chilosi M, Oniga F, Sozzi G, Moro M, Ciccarese F, Nardo G, Bertorelle R, Candiotti C, De Salvo GL, Amadori A, Conte P, Indraccolo S. *LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab*. Clin Cancer Res 2017 **IF: 10.199**
- Morabito A, Gennaro D, Costanzo R, Favaretto A, Filippazzi V, Rossi A, Gebbia V, Castiglione F, Cavanna L, Maiello E, Sandomenico C, **Bonanno L**, Piazza E, Maione M, Piccirillo M C, Di Maio M, Rocco G, Gallo C, Perrone F, Gridelli C. *A multicentre, randomized phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin+etoposide in extensive small cell lung cancer patients (SCLC) patients. The Small-cell lung cancer Toxicity-Adjusted Dosing (STAD-1) trial*. Lung Cancer 2017 **IF: 4.486**
- Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, **Bonanno L**, Polo V, Lunardi F, Attili I, Pavan A, Rugge M, Guarneri V, Conte PF, Pasello G. *Clinical features and treatment outcome of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon or complex Epidermal Growth Factor Receptor (EGFR) mutations*. Oncotarget 2017 **IF: 5.168**
- **Bonanno L**, Calabrese F, Nardo G, Calistri D, Tebaldi M, Tedaldi G, Polo V, Vuljan S, Favaretto A, Conte PF, Amadori A, Rea F, Indraccolo S. *Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: the case of a never-smoker woman*. Lung Cancer 2016 **IF: 4.486**
- **Bonanno L**, Costa C, Majem M, Sanchez J-J, Rodriguez I, Gimenez-Capitan A, Molina-Villa MA, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R. *Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small cell lung cancer*. BMC Cancer 2016 **IF: 3.288**
- Polo V, Pasello G, Frega S, Favaretto A, Koussis H, Conte PF, **Bonanno L**. *Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization*. Oncotarget 2016. **IF: 5.168**
- **Bonanno L**, Zago G, Marulli G, Del Bianco P, Schiavon M, Pasello G, Polo V, Canova F, Tonetto F, Loreggian L, Rea F, Conte PF,

Favaretto A. *Radiological response and survival in locally advanced Non-small cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment*. *Oncotargets and Therapy* 2016. **IF: 1.653**

- Reck M, Rodríguez-Abreu D, Robinson A G, Hui R, Csósz T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki G M, Shentu Y, Rangwala R, Brahmer J R, for the **KEYNOTE-024 Investigators***. *Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer*. *New England Journal of Medicine* 2016 **IF: 72.4**
- Peluso D, Bianchi A, **Bonanno L**, Banzato A. *Unusual echocardiographic appearance of a cardiac metastasis from lung cancer*. *Journal of clinical ultrasound* 2016 **IF: 0.906**
- Di Liso E, Pennelli N, Lodovichetti G, Ghiotto C, Dei Tos AP, Conte PF, **Bonanno L**. *Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature*. *Cancer Biology & Therapy* 2015. **IF: 3.373**
- Polo V, Zago G, Frega S, Canova F, **Bonanno L**, Favaretto A, Bonaldi L, Bertorelle R, Conte PF, Pasello G. *Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature*. *Am J Case Rep* 2015
- Pasello G, Carli P, Canova F, **Bonanno L**, Polo V, Zago G, Urso L, Conte PF, Favaretto A. *Epirubicin plus paclitaxel regimen as second-line treatment of patients with advanced small-cell lung cancer*. *Anticancer Research* 2014 **IF: 1.937**
- Molina-Vila MA, Bertran-Alamillo J, Gascó A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L, **Bonanno L**, Favaretto A, Cardona AF, Vergnenègre A, Majem M, Massuti B, Morán T, Carcereny E, Viteri S, Rosell R. *Nondisruptive p53 mutations are associated with shorter survival in advanced non-small-cell lung cancer patients*. *Clinical Cancer Research* 2014. **IF: 10.199**
- **Bonanno L**, Favaretto A, Rosell R. *Platinum drugs and DNA repair mechanisms in lung cancer*. *Anticancer Research* 2014. **IF: 1.937**
- **Bonanno L**, Costa C, Majem M, Sanchez J-J, Gimenez-Capitan A, Rodriguez I, Vergenègre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R. *The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy*. *Oncotarget* 2013. **IF: 5.168**
- Rosell R & **Bonanno L**. *EGFR inhibitors: patient selection and clinical outcomes*. Chapter 14, *Personalized Management of Lung Cancer*, editor: Komaki R and Liao Z, *Future Medicine* 2013.
- **Bonanno L**, Costa C, Majem M, Favaretto A, Rugge M, Rosell R. *The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy*. *Annals of Oncology* 2013. **IF: 13.926**
- **Bonanno L**. *Predictive models for customizing chemotherapy in advanced Non-small cell lung cancer*. *Translational Lung Cancer Research* 2013.
- **Bonanno L**, Rosell R. *EGFR inhibitors: patient selection & clinical outcomes*. Chapter 9, *Personalized Management of Lung Cancer*, editor: Komaki R and Liao Z, *Future Science Group E-book program* 2013.
- Pasello G, Marulli G, Polo V, Breda C, **Bonanno L**, Loreggian L, Rea F, Favaretto A. *Pemetrexed plus Carboplatin or Cisplatin as Neoadjuvant Treatment of Operable Malignant Pleural Mesothelioma (MPM)*. *Anticancer Res* 2012. **IF: 1.937**
- Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaoli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; **TORCH Investigators**. *Quality of life analysis of TORCH, a randomised trial testing first-line erlotinib followed by second-line cisplatin/gencitabine chemotherapy in advanced Non-small cell lung cancer*. *J Thoracic Oncology* 2012. **IF: 10.336**
- **Bonanno L**, Rosell R. *Customized chemotherapy* (book chapter) in *Perspectives in Thoracic Oncology*, edited by Gautschi O and Peters S, *Uni-Med* 2012.
- Rosell R, **Bonanno L**, Taron M. *Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine* (Chapter 2) in *EGFR inhibitors in cancer treatment*, editor: Ciardiello F, *Future Science Group E-books program* 2012.
- Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, Mukherjee S, Mussolin L, Ruggero K, **Bonanno L**, Guffanti A, De Bellis G, Gerosa G, Stellin G, D'Agostino DM, Basso G, Bronte V, Indraccolo S, Amadori A, Zanovello P. *Modulation of microRNA expression in human T-cell development: targeting NOTCH 3 by miR 150*. *Blood* 2011. **IF: 15.132**
- Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, **Bonanno L**, Masiero M, Ribatti D, Stürzl M, Naschberger E, Croner RS, Jubb AM, Harris AL, Koeppen H, Amadori A, Indraccolo S. *Notch 3 signalling promotes tumor growth in colorectal cancer*. *J Pathol* 2011. **IF: 6.253**
- **Bonanno L**, Favaretto A, Rugge M, Taron M, Rosell R. *Role of genotyping in Non-small-cell lung cancer (NSCLC) treatment: current status*. *Drugs* 2011. **IF: 4.690**
- **Bonanno L**, Jirillo A, Favaretto A. *Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in Non-small cell lung cancer*. *Curr Drug Targets* 2011. **IF: 3.236**
- Pasello G, Nicotra S, Marulli G, Rea F, **Bonanno L**, Carli P, Magro C, Jirillo A, Favaretto A. *Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience*. *Lung cancer* 2011. **IF: 4.486**
- **Bonanno L**, Calvetti L, Favaretto A, Rosell R. *Molecular characterization into clinical practice: current status and future perspectives in advanced Non-small-cell lung cancer*. *Minerva Biotechnologica* 2011. **IF: 0.246**
- **Bonanno L**, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F, Favaretto A. *Prognostic and predictive implications of EGFR mutations, EGFR gene copy number and KRAS mutations in advanced stage lung adenocarcinoma*. *Anticancer Res* 2010. **IF: 1.937**
- Pasello G, Altavilla G, **Bonanno L**, Rea F, Favaretto AG. *A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: a case report*. *Journal of Thoracic disease* 2010. **IF: 1.649**

Reviewer of several journals with impact factor in the field of medical and molecular oncology

I authorize the use of my personal data according to d.lgs 196/03

Laura Bonanno

Padova, 2 July 2018

A handwritten signature in dark ink, appearing to read 'Laura Bonanno', written in a cursive style.